as a result of prioritizing microline , in tandem with its micropine ( progressive myopia ) and microstat ( mydriasis ) programs , the company deferred development activities for its microprost ( glaucoma and ocular hypertension ) and microtears ( red eye and itch relief lubrication ) programs . presbyopia is a non-preventable , age-related hardening of the lens , which causes the gradual loss of the eye 's ability to focus on nearby objects . there currently are no known fda-approved drugs for the improvement of near vision in patients with presbyopia , although other companies have related therapies in their pipeline . eyenovia plans to initiate and complete its phase iii vision trials for microline in 2020. micropine is the company 's first-in-class topical therapy for the treatment of progressive myopia , a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching affecting approximately five million people in the united states . in february 2019 , the fda accepted eyenovia 's investigational new drug application , or ind , to initiate its phase iii registration trial of micropine ( the chaperone study ) to reduce the progression of myopia in children . eyenovia enrolled its first patient in the chaperone study in june 2019 and expects to complete enrollment in 2020. microstat is eyenovia 's fixed combination formulation of phenylephrine-tropicamide for mydriasis , designed to be a novel approach for the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the united states . eyenovia has completed its phase iii trials for microstat and announced positive results from these studies , known as mist-1 and mist-2 . with the primary objectives of its phase iii program for microstat met , eyenovia plans to submit a new drug application , or nda , to the fda in 2020 for marketing approval in the united states . results from our previous three phase ii clinical trials have been published in peer-reviewed literature . two studies evaluating our mydriatic agents demonstrated how the optejet consistently delivered precision dosing at the volume of the eye 's natural tear film capacity of 6-8 µl , which reduced ocular and systemic drug and preservative exposure , while demonstrating pupil dilation comparable to conventional eye drops with fewer side effects . in the third study , we evaluated usability , patient tolerability and iop lowering of microdosed latanoprost administered with the optejet . in this study , eyes receiving microdosed latanoprost achieved iop reduction consistent with published literature on latanoprost eye drops , and administration of the medication was successful in a single attempt in more than 90 % of cases . based on the results from these clinical trials , we are advancing microline , micropine , microstat , and microprost ( should we resume the program ) utilizing the 505 ( b ) ( 2 ) pathway . where possible , we also intend to use this pathway for future clinical trials in new indications with significant unmet needs . we have not completed development of any product candidate and we have therefore not generated any revenues from product sales . historically , we have financed our operations principally through stock offerings , including our initial public offering and follow-on public offering that closed in january and december 2018 , respectively and our public offering that closed in july 2019. based upon our current operating plan , substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included elsewhere in this annual report on form 10-k are issued exists . our ability to continue as a going concern depends on our ability to raise additional capital , through the sale of equity or debt securities to support our future operations . if the company is unable to secure additional capital , it may be required to curtail its research and development initiatives and take additional measures to reduce costs . our net loss was $ 21.2 million for the year ended december 31 , 2019. as of december 31 , 2019 , we had working capital of $ 11.4 million and an accumulated deficit of $ 57.7 million . financial overview revenue we have not generated any revenue from product sales since our inception and do not expect to generate any revenue from the sale of products in the near future . our ability to generate revenues will depend heavily on the successful development , regulatory approval and commercialization of our microdose therapeutic product candidates . 62 research and development expenses research and development expenses are incurred in connection with the research and development of our microdose- therapeutics and consist primarily of contract service expenses . given where we are in our life cycle , we do not separately track research and development expenses by project . our research and development expenses consist of : · direct clinical and non-clinical expenses , which include expenses incurred under agreements with contract research organizations , contract manufacturing organizations , and costs associated with preclinical activities , development activities and regulatory activities ; · personnel-related expenses , which include expenses related to consulting agreements with individuals that have since entered into employment agreements with us as well as salaries and other compensation of employees that is attributable to research and development activities ; and · facilities and other expenses , which include direct and allocated expenses for rent and maintenance of facilities , marketing , insurance and other supplies used in research and development activities . we expense research and development costs as incurred . we record costs for some development activities , such as clinical trials , based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment , clinical site activations or other information our vendors provide to us . we expect that our research and development expenses will increase with the continuation of the story_separator_special_tag as a result of prioritizing microline , in tandem with its micropine ( progressive myopia ) and microstat ( mydriasis ) programs , the company deferred development activities for its microprost ( glaucoma and ocular hypertension ) and microtears ( red eye and itch relief lubrication ) programs . presbyopia is a non-preventable , age-related hardening of the lens , which causes the gradual loss of the eye 's ability to focus on nearby objects . there currently are no known fda-approved drugs for the improvement of near vision in patients with presbyopia , although other companies have related therapies in their pipeline . eyenovia plans to initiate and complete its phase iii vision trials for microline in 2020. micropine is the company 's first-in-class topical therapy for the treatment of progressive myopia , a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching affecting approximately five million people in the united states . in february 2019 , the fda accepted eyenovia 's investigational new drug application , or ind , to initiate its phase iii registration trial of micropine ( the chaperone study ) to reduce the progression of myopia in children . eyenovia enrolled its first patient in the chaperone study in june 2019 and expects to complete enrollment in 2020. microstat is eyenovia 's fixed combination formulation of phenylephrine-tropicamide for mydriasis , designed to be a novel approach for the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the united states . eyenovia has completed its phase iii trials for microstat and announced positive results from these studies , known as mist-1 and mist-2 . with the primary objectives of its phase iii program for microstat met , eyenovia plans to submit a new drug application , or nda , to the fda in 2020 for marketing approval in the united states . results from our previous three phase ii clinical trials have been published in peer-reviewed literature . two studies evaluating our mydriatic agents demonstrated how the optejet consistently delivered precision dosing at the volume of the eye 's natural tear film capacity of 6-8 µl , which reduced ocular and systemic drug and preservative exposure , while demonstrating pupil dilation comparable to conventional eye drops with fewer side effects . in the third study , we evaluated usability , patient tolerability and iop lowering of microdosed latanoprost administered with the optejet . in this study , eyes receiving microdosed latanoprost achieved iop reduction consistent with published literature on latanoprost eye drops , and administration of the medication was successful in a single attempt in more than 90 % of cases . based on the results from these clinical trials , we are advancing microline , micropine , microstat , and microprost ( should we resume the program ) utilizing the 505 ( b ) ( 2 ) pathway . where possible , we also intend to use this pathway for future clinical trials in new indications with significant unmet needs . we have not completed development of any product candidate and we have therefore not generated any revenues from product sales . historically , we have financed our operations principally through stock offerings , including our initial public offering and follow-on public offering that closed in january and december 2018 , respectively and our public offering that closed in july 2019. based upon our current operating plan , substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included elsewhere in this annual report on form 10-k are issued exists . our ability to continue as a going concern depends on our ability to raise additional capital , through the sale of equity or debt securities to support our future operations . if the company is unable to secure additional capital , it may be required to curtail its research and development initiatives and take additional measures to reduce costs . our net loss was $ 21.2 million for the year ended december 31 , 2019. as of december 31 , 2019 , we had working capital of $ 11.4 million and an accumulated deficit of $ 57.7 million . financial overview revenue we have not generated any revenue from product sales since our inception and do not expect to generate any revenue from the sale of products in the near future . our ability to generate revenues will depend heavily on the successful development , regulatory approval and commercialization of our microdose therapeutic product candidates . 62 research and development expenses research and development expenses are incurred in connection with the research and development of our microdose- therapeutics and consist primarily of contract service expenses . given where we are in our life cycle , we do not separately track research and development expenses by project . our research and development expenses consist of : · direct clinical and non-clinical expenses , which include expenses incurred under agreements with contract research organizations , contract manufacturing organizations , and costs associated with preclinical activities , development activities and regulatory activities ; · personnel-related expenses , which include expenses related to consulting agreements with individuals that have since entered into employment agreements with us as well as salaries and other compensation of employees that is attributable to research and development activities ; and · facilities and other expenses , which include direct and allocated expenses for rent and maintenance of facilities , marketing , insurance and other supplies used in research and development activities . we expense research and development costs as incurred . we record costs for some development activities , such as clinical trials , based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment , clinical site activations or other information our vendors provide to us . we expect that our research and development expenses will increase with the continuation of the

liquidity and going concern since inception , we have experienced negative cash flows from operations . at december 31 , 2019 , our accumulated deficit since inception was $ 57.7 million . at december 31 , 2019 , we had working capital of $ 11.4 million and stockholders ' equity of $ 11.7 million . at december 31 , 2019 and 2018 , we had no debt outstanding . at december 31 , 2019 , we had a cash and cash equivalents balance of $ 14.2 million . these conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included elsewhere in this annual report on form 10-k are issued . our financial statements do not include adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern . our ability to continue as a going concern depends on our ability to raise additional capital , through the sale of equity or debt securities to support our future operations . our operating needs include the planned costs to operate our business , including amounts required to fund research and development activities including clinical studies , working capital and capital expenditures .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and going concern since inception , we have experienced negative cash flows from operations . at december 31 , 2019 , our accumulated deficit since inception was $ 57.7 million . at december 31 , 2019 , we had working capital of $ 11.4 million and stockholders ' equity of $ 11.7 million . at december 31 , 2019 and 2018 , we had no debt outstanding . at december 31 , 2019 , we had a cash and cash equivalents balance of $ 14.2 million . these conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included elsewhere in this annual report on form 10-k are issued . our financial statements do not include adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern . our ability to continue as a going concern depends on our ability to raise additional capital , through the sale of equity or debt securities to support our future operations . our operating needs include the planned costs to operate our business , including amounts required to fund research and development activities including clinical studies , working capital and capital expenditures .
```    
 Suspicious Activity Report : as a result of prioritizing microline , in tandem with its micropine ( progressive myopia ) and microstat ( mydriasis ) programs , the company deferred development activities for its microprost ( glaucoma and ocular hypertension ) and microtears ( red eye and itch relief lubrication ) programs . presbyopia is a non-preventable , age-related hardening of the lens , which causes the gradual loss of the eye 's ability to focus on nearby objects . there currently are no known fda-approved drugs for the improvement of near vision in patients with presbyopia , although other companies have related therapies in their pipeline . eyenovia plans to initiate and complete its phase iii vision trials for microline in 2020. micropine is the company 's first-in-class topical therapy for the treatment of progressive myopia , a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching affecting approximately five million people in the united states . in february 2019 , the fda accepted eyenovia 's investigational new drug application , or ind , to initiate its phase iii registration trial of micropine ( the chaperone study ) to reduce the progression of myopia in children . eyenovia enrolled its first patient in the chaperone study in june 2019 and expects to complete enrollment in 2020. microstat is eyenovia 's fixed combination formulation of phenylephrine-tropicamide for mydriasis , designed to be a novel approach for the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the united states . eyenovia has completed its phase iii trials for microstat and announced positive results from these studies , known as mist-1 and mist-2 . with the primary objectives of its phase iii program for microstat met , eyenovia plans to submit a new drug application , or nda , to the fda in 2020 for marketing approval in the united states . results from our previous three phase ii clinical trials have been published in peer-reviewed literature . two studies evaluating our mydriatic agents demonstrated how the optejet consistently delivered precision dosing at the volume of the eye 's natural tear film capacity of 6-8 µl , which reduced ocular and systemic drug and preservative exposure , while demonstrating pupil dilation comparable to conventional eye drops with fewer side effects . in the third study , we evaluated usability , patient tolerability and iop lowering of microdosed latanoprost administered with the optejet . in this study , eyes receiving microdosed latanoprost achieved iop reduction consistent with published literature on latanoprost eye drops , and administration of the medication was successful in a single attempt in more than 90 % of cases . based on the results from these clinical trials , we are advancing microline , micropine , microstat , and microprost ( should we resume the program ) utilizing the 505 ( b ) ( 2 ) pathway . where possible , we also intend to use this pathway for future clinical trials in new indications with significant unmet needs . we have not completed development of any product candidate and we have therefore not generated any revenues from product sales . historically , we have financed our operations principally through stock offerings , including our initial public offering and follow-on public offering that closed in january and december 2018 , respectively and our public offering that closed in july 2019. based upon our current operating plan , substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included elsewhere in this annual report on form 10-k are issued exists . our ability to continue as a going concern depends on our ability to raise additional capital , through the sale of equity or debt securities to support our future operations . if the company is unable to secure additional capital , it may be required to curtail its research and development initiatives and take additional measures to reduce costs . our net loss was $ 21.2 million for the year ended december 31 , 2019. as of december 31 , 2019 , we had working capital of $ 11.4 million and an accumulated deficit of $ 57.7 million . financial overview revenue we have not generated any revenue from product sales since our inception and do not expect to generate any revenue from the sale of products in the near future . our ability to generate revenues will depend heavily on the successful development , regulatory approval and commercialization of our microdose therapeutic product candidates . 62 research and development expenses research and development expenses are incurred in connection with the research and development of our microdose- therapeutics and consist primarily of contract service expenses . given where we are in our life cycle , we do not separately track research and development expenses by project . our research and development expenses consist of : · direct clinical and non-clinical expenses , which include expenses incurred under agreements with contract research organizations , contract manufacturing organizations , and costs associated with preclinical activities , development activities and regulatory activities ; · personnel-related expenses , which include expenses related to consulting agreements with individuals that have since entered into employment agreements with us as well as salaries and other compensation of employees that is attributable to research and development activities ; and · facilities and other expenses , which include direct and allocated expenses for rent and maintenance of facilities , marketing , insurance and other supplies used in research and development activities . we expense research and development costs as incurred . we record costs for some development activities , such as clinical trials , based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment , clinical site activations or other information our vendors provide to us . we expect that our research and development expenses will increase with the continuation of the story_separator_special_tag as a result of prioritizing microline , in tandem with its micropine ( progressive myopia ) and microstat ( mydriasis ) programs , the company deferred development activities for its microprost ( glaucoma and ocular hypertension ) and microtears ( red eye and itch relief lubrication ) programs . presbyopia is a non-preventable , age-related hardening of the lens , which causes the gradual loss of the eye 's ability to focus on nearby objects . there currently are no known fda-approved drugs for the improvement of near vision in patients with presbyopia , although other companies have related therapies in their pipeline . eyenovia plans to initiate and complete its phase iii vision trials for microline in 2020. micropine is the company 's first-in-class topical therapy for the treatment of progressive myopia , a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching affecting approximately five million people in the united states . in february 2019 , the fda accepted eyenovia 's investigational new drug application , or ind , to initiate its phase iii registration trial of micropine ( the chaperone study ) to reduce the progression of myopia in children . eyenovia enrolled its first patient in the chaperone study in june 2019 and expects to complete enrollment in 2020. microstat is eyenovia 's fixed combination formulation of phenylephrine-tropicamide for mydriasis , designed to be a novel approach for the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the united states . eyenovia has completed its phase iii trials for microstat and announced positive results from these studies , known as mist-1 and mist-2 . with the primary objectives of its phase iii program for microstat met , eyenovia plans to submit a new drug application , or nda , to the fda in 2020 for marketing approval in the united states . results from our previous three phase ii clinical trials have been published in peer-reviewed literature . two studies evaluating our mydriatic agents demonstrated how the optejet consistently delivered precision dosing at the volume of the eye 's natural tear film capacity of 6-8 µl , which reduced ocular and systemic drug and preservative exposure , while demonstrating pupil dilation comparable to conventional eye drops with fewer side effects . in the third study , we evaluated usability , patient tolerability and iop lowering of microdosed latanoprost administered with the optejet . in this study , eyes receiving microdosed latanoprost achieved iop reduction consistent with published literature on latanoprost eye drops , and administration of the medication was successful in a single attempt in more than 90 % of cases . based on the results from these clinical trials , we are advancing microline , micropine , microstat , and microprost ( should we resume the program ) utilizing the 505 ( b ) ( 2 ) pathway . where possible , we also intend to use this pathway for future clinical trials in new indications with significant unmet needs . we have not completed development of any product candidate and we have therefore not generated any revenues from product sales . historically , we have financed our operations principally through stock offerings , including our initial public offering and follow-on public offering that closed in january and december 2018 , respectively and our public offering that closed in july 2019. based upon our current operating plan , substantial doubt about our ability to continue as a going concern for a period of at least one year from the date that the financial statements included elsewhere in this annual report on form 10-k are issued exists . our ability to continue as a going concern depends on our ability to raise additional capital , through the sale of equity or debt securities to support our future operations . if the company is unable to secure additional capital , it may be required to curtail its research and development initiatives and take additional measures to reduce costs . our net loss was $ 21.2 million for the year ended december 31 , 2019. as of december 31 , 2019 , we had working capital of $ 11.4 million and an accumulated deficit of $ 57.7 million . financial overview revenue we have not generated any revenue from product sales since our inception and do not expect to generate any revenue from the sale of products in the near future . our ability to generate revenues will depend heavily on the successful development , regulatory approval and commercialization of our microdose therapeutic product candidates . 62 research and development expenses research and development expenses are incurred in connection with the research and development of our microdose- therapeutics and consist primarily of contract service expenses . given where we are in our life cycle , we do not separately track research and development expenses by project . our research and development expenses consist of : · direct clinical and non-clinical expenses , which include expenses incurred under agreements with contract research organizations , contract manufacturing organizations , and costs associated with preclinical activities , development activities and regulatory activities ; · personnel-related expenses , which include expenses related to consulting agreements with individuals that have since entered into employment agreements with us as well as salaries and other compensation of employees that is attributable to research and development activities ; and · facilities and other expenses , which include direct and allocated expenses for rent and maintenance of facilities , marketing , insurance and other supplies used in research and development activities . we expense research and development costs as incurred . we record costs for some development activities , such as clinical trials , based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment , clinical site activations or other information our vendors provide to us . we expect that our research and development expenses will increase with the continuation of the

